71 related articles for article (PubMed ID: 26456124)
21. MicroRNA-126 suppresses proliferation of undifferentiated (BRAF(V600E) and BRAF(WT)) thyroid carcinoma through targeting PIK3R2 gene and repressing PI3K-AKT proliferation-survival signalling pathway.
Rahman MA; Salajegheh A; Smith RA; Lam AK
Exp Cell Res; 2015 Dec; 339(2):342-50. PubMed ID: 26384552
[TBL] [Abstract][Full Text] [Related]
22. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma.
Sheu SY; Grabellus F; Schwertheim S; Handke S; Worm K; Schmid KW
Horm Metab Res; 2009 Jun; 41(6):482-7. PubMed ID: 19370505
[TBL] [Abstract][Full Text] [Related]
23. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
24. Integrated Analysis of Thyroid Cancer Public Datasets Reveals Role of Post-Transcriptional Regulation on Tumor Progression by Targeting of Immune System Mediators.
Geraldo MV; Kimura ET
PLoS One; 2015; 10(11):e0141726. PubMed ID: 26536459
[TBL] [Abstract][Full Text] [Related]
25. Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations.
Ho YJ; Anaparthy N; Molik D; Mathew G; Aicher T; Patel A; Hicks J; Hammell MG
Genome Res; 2018 Sep; 28(9):1353-1363. PubMed ID: 30061114
[TBL] [Abstract][Full Text] [Related]
26. Genome-wide analysis of miRNA signature differentially expressed in doxorubicin-resistant and parental human hepatocellular carcinoma cell lines.
Zhang J; Wang Y; Zhen P; Luo X; Zhang C; Zhou L; Lu Y; Yang Y; Zhang W; Wan J
PLoS One; 2013; 8(1):e54111. PubMed ID: 23359607
[TBL] [Abstract][Full Text] [Related]
27. miR-146b is highly expressed in adult papillary thyroid carcinomas with high risk features including extrathyroidal invasion and the BRAF(V600E) mutation.
Chou CK; Chen RF; Chou FF; Chang HW; Chen YJ; Lee YF; Yang KD; Cheng JT; Huang CC; Liu RT
Thyroid; 2010 May; 20(5):489-94. PubMed ID: 20406109
[TBL] [Abstract][Full Text] [Related]
28. Tunicamycin induces paraptosis potentiated by inhibition of BRAFV600E in FRO anaplastic thyroid carcinoma cells.
Kim SH; Shin HY; Kim YS; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2014 Sep; 34(9):4857-68. PubMed ID: 25202067
[TBL] [Abstract][Full Text] [Related]
29. A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification.
Dugo M; Nicolini G; Tragni G; Bersani I; Tomassetti A; Colonna V; Del Vecchio M; De Braud F; Canevari S; Anichini A; Sensi M
Oncotarget; 2015 Mar; 6(7):5118-33. PubMed ID: 25742786
[TBL] [Abstract][Full Text] [Related]
30. The BH3-mimetic ABT-737 sensitizes human melanoma cells to apoptosis induced by selective BRAF inhibitors but does not reverse acquired resistance.
Wroblewski D; Mijatov B; Mohana-Kumaran N; Lai F; Gallagher SJ; Haass NK; Zhang XD; Hersey P
Carcinogenesis; 2013 Feb; 34(2):237-47. PubMed ID: 23087082
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
[TBL] [Abstract][Full Text] [Related]
32. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma.
Stark MS; Bonazzi VF; Boyle GM; Palmer JM; Symmons J; Lanagan CM; Schmidt CW; Herington AC; Ballotti R; Pollock PM; Hayward NK
Oncotarget; 2015 Jul; 6(19):17753-63. PubMed ID: 25980496
[TBL] [Abstract][Full Text] [Related]
33. The c-Jun/RHOB/AKT pathway confers resistance of BRAF-mutant melanoma cells to MAPK inhibitors.
Delmas A; Cherier J; Pohorecka M; Medale-Giamarchi C; Meyer N; Casanova A; Sordet O; Lamant L; Savina A; Pradines A; Favre G
Oncotarget; 2015 Jun; 6(17):15250-64. PubMed ID: 26098773
[TBL] [Abstract][Full Text] [Related]
34. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
35. Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a.
Pacifico F; Crescenzi E; Mellone S; Iannetti A; Porrino N; Liguoro D; Moscato F; Grieco M; Formisano S; Leonardi A
J Clin Endocrinol Metab; 2010 Mar; 95(3):1421-30. PubMed ID: 20061417
[TBL] [Abstract][Full Text] [Related]
36. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
[TBL] [Abstract][Full Text] [Related]
37. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma.
Sheu SY; Vogel E; Worm K; Grabellus F; Schwertheim S; Schmid KW
Histopathology; 2010 Apr; 56(5):632-40. PubMed ID: 20459574
[TBL] [Abstract][Full Text] [Related]
38. Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2.
Hicks HM; Pozdeyev N; Sams SB; Pugazhenthi U; Bales ES; Hofmann MC; McKenna LR; Schweppe RE
Mol Cancer Res; 2023 Sep; 21(9):867-880. PubMed ID: 37219859
[TBL] [Abstract][Full Text] [Related]
39. Altered expression of mir-222 and mir-25 influences diverse gene expression changes in transformed normal and anaplastic thyroid cells, and impacts on MEK and TRAIL protein expression.
Aherne ST; Smyth P; Freeley M; Smith L; Spillane C; O'Leary J; Sheils O
Int J Mol Med; 2016 Aug; 38(2):433-45. PubMed ID: 27353001
[TBL] [Abstract][Full Text] [Related]
40. Propranolol sensitizes thyroid cancer cells to cytotoxic effect of vemurafenib.
Wei WJ; Shen CT; Song HJ; Qiu ZL; Luo QY
Oncol Rep; 2016 Sep; 36(3):1576-84. PubMed ID: 27432558
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]